key: cord-1051407-6ikziooc
authors: Lu, J.; Peng, J.; Xiong, Q.; Liu, Z.; Lin, H.; Tan, X.; Kang, M.; Yuan, R.; Zeng, L.; Zhou, P.; Liang, C.; Yi, L.; Plessis, L. d.; Song, T.; Ma, W.; Sun, J.; Pybus, O.; Ke, C.
title: Clinical, immunological and virological characterization of COVID-19 patients that test re-positive for SARS-CoV-2 by RT-PCR
date: 2020-06-17
journal: nan
DOI: 10.1101/2020.06.15.20131748
sha: 5d3ab65cc04ea044d3a8918dd3a8552f0e0a71ed
doc_id: 1051407
cord_uid: 6ikziooc

Background COVID-19 pandemic is underway. Some COVID-19 cases re-tested positive for SARS-CoV-2 RNA after discharge raising the public concern on their infectivity. Characterization of re-positive cases are urgently needed for designing intervention strategies. Methods Clinical data were obtained through Guangdong COVID-19 surveillance network. Neutralization antibody titre was determined using a microneutralization assay. Potential infectivity of clinical samples was evaluated after the cell inoculation. SARS-CoV-2 RNA was detected using three different RT-PCR kits and multiplex PCR with nanopore sequencing. Results Among 619 discharged COVID-19 cases, 87 were re-tested as SARS-CoV-2 positive in circumstance of social isolation. All re-positive cases had mild or moderate symptoms in initial diagnosis and a younger age distribution (mean, 30.4). Re-positive cases (n=59) exhibited similar neutralization antibodies (NAbs) titre distributions to other COVID-19 cases (n=150) parallel-tested in this study. No infective viral strain could be obtained by culture and none full-length viral genomes could be sequenced for all re-positive cases. Conclusions Re-positive SARS-CoV-2 was not caused by the secondary infection and was identified in around 14% of discharged cases. A robust Nabs response and a potential virus genome degradation were detected from nearly all re-positive cases suggesting a lower transmission risk, especially through a respiratory route.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020 . . https://doi.org/10.1101 /2020 Serum samples were collected from re-positive cases, cases in hospitalization and general discharged COVID-19 1 0 5 cases at more than 21 days post illness onset. Microneutralization antibody assays for SARS-CoV-2 were 1 0 6 performed in a BSL-3 laboratory according to the standard protocol of a neutralization test. A local SARS-CoV-2 1 0 7 strain isolated from the first COVID-19 patient in Guangdong (GISAID accession ID: EPI_ISL_403934) was 1 0 8 used microneutralization assay. All neutralizing antibody assays were run in 96-well microplates. Serum samples 1 0 9

were inactivated at 56°C for 30 mins before use, diluted two-fold from 1:4 to 1:1,024, and then incubated at 37°C 1 1 0 for 2 hours with equal volumes of 100 half tissue culture infective doses (100 TCID50). Thereafter, the mixture changes relative to the reference sequence (MN908947). Assembly of the nanopore raw data was performed using 1 2 4

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020 . . https://doi.org/10.1101 /2020 the ARTIC bioinformatic pipeline for COVID-19 with minimap2 (10) and medaka 1 2 5 of Guangdong province to be part of a continuing public health outbreak investigation during the emergency 1 4 2 response and were thus considered exempt from institutional review board approval.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131748 doi: medRxiv preprint 1 0

Clinical characteristics of re-positive cases 1 4 5

A total of 619 COVID-19 cases were discharged from designated hospitals between 23 January and 19 February, 1 4 6 2020. These cases were continuously isolated in designated hotels and were all screened for SARS-CoV-2 after An impaired immune response has been associated with fatal COVID-19 infections that exhibit prolonged 1 6 2

persistence of viral RNA (13). One possible explanation for the re-positive detection of SARS-CoV-2 RNA is that 1 6 3 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. Figure 1A ). Serum samples were collected at a median of 35 days post illness onset (ranging from 23 to 47 days).

As a comparation, 150 serum samples from general discharged cases (n=38) and cases in hospitalization (n=112) (Table S1 ). RT-PCR positive rates were not statistically different 1 8 3

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. (Figure 2 ). We find that the 1 8 6 duration from discharge to the time tested as re-positive can range from 6 to 28 days ( Figure 2) . Importantly, Virus whole genome sequencing in re-positive cases 1 9 5

A previously study proved virus isolation success was also depended on viral load, and samples containing <10 6 1 9 6 copies/mL (or copies per sample) never yielded an isolate (3). For acute infection cases, we found that high 1 9 7 quality SARS-CoV-2 genomes could be obtained by using a multiplex PCR method even for samples with a low 1 9 8 viral load (8). Therefore, the successive detection of a complete or nearly complete viral genome may provide 1 9 9

clues on the status of viral replication. None of full-length SARS-CoV-2 genome could be obtained by All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. Guangdong COVID-19 surveillance system to analyse the characteristics of re-positive cases in Guangdong 2 2 0 between 23 January and 26 February, and we explore questions such as the percentage, immune status and 2 2 1 infectivity of re-positive cases.

2 2 2 2 2 3 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131748 doi: medRxiv preprint 1 4

The first question we addressed is the re-positive rate in COVID-19 discharged cases. Here, the discharge 2 2 4 criteria are according to the Diagnosis and Treatment Scheme of SARS-CoV-2 (see Methods for detail). By 2 2 5 screening 619 discharged cases, up to 25 February, the percentage of SARS-CoV-2 re-positive cases is around 2 2 6

14%. According to the scheme, all discharged cases are continuously isolated in designated hotels with strict 2 2 7

interventions on diseases transmission. Thus, the identification of re-positive SARS-CoV-2 during the isolation 2 2 8 phase exclude the possibility that re-positive cases is caused by the secondary viral infection. Our results also 2 2 9

highlight a significant feature of re-positive cases. All re-re-positive cases in our study developed only mild or 2 3 0 moderate symptoms in the initial diagnosis, with the median age significantly lower than that of the general 2 3 1 COVID-19 cases ( (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted June 17, 2020. (3), infectivity may not accurately illustrated by the culture method 2 4 9

although no viral isolates were obtained from RT-PCR positive samples. Thus, we also perform the multiplex 2 5 0 PCR combined with high-throughput sequencing on these samples. The discrepancy we observed among 2 5 1 different RT-PCR kit results, as well as between RT-PCR and multiplex PCR sequencing results, suggests that 2 5 2 the virus genomes detected in re-positive cases could be highly degraded. We only recovered one virus sequence 2 5 3 with genome coverage >20% (34.5%) in 23 RT-PCR positive respiratory samples ( Figure 3A ). These results 2 5 4 suggest a low residual risk of infectivity of re-positive cases, especially from the respiratory transmission route. Several limitations of our study should also be noted. First, we did not obtain successively collected samples, 2 5 7 resulting in the existence of bias toward the summarized duration from the discharge to firstly re-positive result 2 5 8

for viral RNA as well as the time of the re-positive RNA to negative. Secondly, we did not obtain the 2 5 9

corresponding samples during the acute infection for these re-positive cases. Therefore, some virologic 2 6 0 questions remain, including whether there any genetic differences for SARS-CoV-2 viruses sampled in an acute 2 6 1 infection phase and a re-positive phase. The significance of SNVs identified in different samples of re-positive 2 6 2 cases is limited by the sample size ( Figure 3A ) and should be further clarified in following studies. 

Discharge-sampling N/A 6

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020 . . https://doi.org/10.1101 /2020 Appropriate design intervention strategies on COVID-19 has been largely relied on how well we understand the 2 6 5 characteristics of the SARS-CoV-2 infection. Re-positive of viral RNA in some discharged cases could raise a 2 6 6 challenge for disease interventions which means a prolonged isolation phase and a more requirement on hospital 2 6 7 isolation facilities. Our study result shows a comparable Nab response in re-positive cases comparing to other 2 6 8 COVID-19 cases. More importantly, none of infective strains could be successfully isolated and no intact viral 2 6 9 genome could be sequenced from all re-positive cases samples highlighting a lower risk for disease transmission 2 7 0 from such cases. The additional educations related on SARS-CoV-2 re-positive should be performed to calm 2 7 1 down the public panic and allocate of limited medical resources.

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. Guangdong(2018B020207006), National Science and Technology Project(2020YFC0846800).

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. China. Nature 1-8. 5. WHO. 2020. Coronavirus disease (COVID-2019) situation reports.

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. China. Cell S0092867420304864. 34:3094-3100.

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. Bioinformatics 15:14-18. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. Gender All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020 . . https://doi.org/10.1101 /2020 All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10.1101/2020.06.15.20131748 doi: medRxiv preprint 2 6 3 5 7All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted June 17, 2020. . https://doi.org/10. 1101 /2020